AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00424645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voraxaze (Glucarpidase)
Description: 50 units/kg IV within 12 hours of study eligibility being confirmed.
Study NCT00424645 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by IV within 12 hours of study eligibility being confirmed.
Study NCT04290819 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine Monohydrate
Description: 0.1g/kg of body weight (pre measured creatine) and 3mg/kg of body weight (pre measured micronized cellulose powder-caffeine placebo) self administered 1 hr prior to working out mixed in water.
Study NCT03677310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% Sodium Chloride
Description: 3% sodium chloride will be given intravenously at a rate of 10 cc/hour over a period of 24 hours beginning immediately prior to incision.
Study NCT04290819 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine Monohydrate and Caffeine
Description: 0.1g/kg body weight (pre measured creatine) and 3mg/kg body weight (pre measured caffeine) self administered 1hr prior to working out mixed in water.
Study NCT04290819 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: 3mg/kg of body weight (pre measured caffeine) and 0.1g/kg of bodyweight (pre measured maltodextrin- creatine placebo) self administered 1 hr prior to working out mixed in water.
Study NCT04290819 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.1g/kg of body weight (pre measured maltodextrin) and 3mg/kg of body weight (pre measured micronized cellulose powder) self administered 1 hr prior to working out mixed in water.
Study NCT01946191 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 24 months of personalized coaching through the EHR patient portal, with 24 scheduled contacts.
Description: Participants were assigned to a specific coach, who contacted the participants via the EHR weekly for 1 month, biweekly in months 2 to 6, monthly in months 7 to 12, and quarterly in months 13 to 24, for a total of 24 scheduled contacts. Coaching group participants received brief questionnaires relevant to weight management, including a text field where they could discuss questions or barriers. On the basis of participant responses and self-monitoring data in the EHR flow sheets, coaches wrote a brief personalized note with advice on questionnaire topics and responses to any queries or barriers mentioned by the participant. Coaching participants who did not complete questionnaires or log information into the flow sheet for 2 weeks were considered inactive and were contacted by telephone or e-mail and invited to reengage at any time. Coaching participants were able to send secure messages to the coach.
Study NCT01946191 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online self-monitoring
Description: Participants were encouraged to log in daily and enter data on weight, diet, and physical activity.
Study NCT01946191 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online self-monitoring
Description: Participants were encouraged to log in daily and enter data on weight, diet, and physical activity.
Study NCT01946191 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Real-time updates to Primary Care physicians
Description: Referring PCPs of coaching group participants received regular support, including real-time progress reports with counseling tips delivered via the EHR, notification of weight change in increments of at least 10 pounds, and annual progress reports at 12 and 24 months.
Study NCT04401462 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tension band wiring or plate fixation
Description: Operative fixation of olecranon fracture with either of the methods mentioned in the intervention name
Study NCT04401462 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sling or a long-arm plaster
Description: Non-operative treatment and progressive range of motion as tolerated. A long-arm plaster will be used, if necessary, for pain relief.
Study NCT03405714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: * Pharmaceutical form: Solution for iv injection~* Route of administration: intravenous use~* Concentration: 10 mg/ml
Study NCT03811470 — intervention group
Intervention type: OTHER
Intervention: Standard diabetes management model in each MMC center
Description: Standard diabetes management model in each MMC center
Study NCT02459015 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation
Description: A peripheral nerve defect up to 26 mm in the finger will be repaired by implantation of either a Reaxon® Nerve Guide or an autologous nerve graft (depending on the randomization group) on day 0.
Study NCT02459015 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation
Description: A peripheral nerve defect up to 26 mm in the finger will be repaired by implantation of either a Reaxon® Nerve Guide or an autologous nerve graft (depending on the randomization group) on day 0.
Study NCT03677310 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline will be given intravenously at a rate of 10 cc/hour over a period of 24 hours beginning immediately prior to incision.
Study NCT02247674 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral movement training
Description: Exercise training of bilateral isometric handgrip force training group consisted of 60 minutes of bilateral isometric handgrip force training 3 days per week for 4 weeks (total 12 sessions)
Study NCT02247674 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bilateral movement training
Description: Exercise training of bilateral isometric handgrip force training group consisted of 60 minutes of bilateral isometric handgrip force training 3 days per week for 4 weeks (total 12 sessions)
Study NCT01956266 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional prosodic treatment
Description: The experimental treatment is consistent with the standard treatment in that it targets impairments in pitch/stress, loudness variability and control of speech rate, the core characteristics of prosodic insufficiency in PD (Darley, Aronson \& Brown, 1969). However, the experimental treatment provides an innovative and targeted emphasis on the emotional component of the disorder. The production of emotional intonation in an utterance requires varying combinations of pitch/stress, loudness, and rate. Participants will receive clinician feedback as well as auditory and visual feedback on accuracy via the VisiPitch display.
Study NCT04151355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20mg
Description: atorvastatin (20 mg once daily)
Study NCT00981318 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: lopinavir/ritonavir plus maraviroc
Description: lopinavir/ritonavir 400/100 mg bid plus maraviroc 150 mg bid
Study NCT04315480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: single intravenous administration 8mg/Kg
Study NCT04121520 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: 1. Comprehensive perioperative assessment~2. Questionnaire administration
Study NCT02344420 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Echocardiography
Description: The devices used within the study are the legally marked CRT devices from BIOTRONIK. CRT-P and CRT-D. As this is a post market study, all devices have a CE label and are used within their intended use. There are no study specific limitations nor mandatory device settings for the study.~Subjects will undergo a standard echo assessment at baseline, 6 and 12 month follow up visit in order to assess the baseline characteristics and the changes as response to resynchronization.
Study NCT02344420 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Minnesota Living Heart Failure Questionnaire (MLHF)
Description: MLHF will be obtained at baseline, 6 and 12 month FU. The goal of this questionnaire is to measure the subjects perception of how their heart failure and treatment affect their life. Questions are focused on physical, socio-economic, and psychological impairments that persons with congestive heart failure frequently attribute to their condition.
Study NCT02344420 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Six minute walk test
Description: The test will be performed at baseline, 6 and 12 month FU. The purpose of the test is to determine how far a patient can walk in six minute and relate it with the heart failure.
Study NCT01602965 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Counseling Monthly Phone Calls
Description: the dietician will call the patient at home, and invite them to answer 11 open questions.The questionnaire collects information about weight loss, behaviors that need to be changed, problem-solving as to how to make the changes and physical activity levels.
Study NCT01602965 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Self Help Informative Booklet
Description: Self help informative booklet includes information on how to manage healthy weight, how to lose weight, physical activity and a simplified and abbreviated version of the main behavioural strategies
Study NCT02939950 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bausch + Lomb Samfilcon A Soft Contact Lens
Description: soft contact lenses
Study NCT02939950 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bausch + Lomb Pure Vision Soft Contact Lens
Description: soft contact lenses
Study NCT02349971 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR-HIFU
Description: Magnetic Resonance guided High Intensity Focused Ultrasound (MR-HIFU) provides precise and controlled delivery of focused ultrasound energy inside a lesion using an external applicator, without the need for a scalpel or needle
Study NCT01851018 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofraction
Description: Patient reported toxicities related to Hypofraction radiation treatment (3 Gy daily, 5 fractions per week) up to a total of 36 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant firmagon (240 mg given as two subcutaneous injections of 120 mg at a concentration of 40 mg/mL as a starting dose with a maintenance dose of 80 mg given as one subcutaneous injection at a concentration of 20 mg/mL administered every 28 days).
Study NCT01851018 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Patient reported toxicities related to the Standard radiation treatment (2 Gy daily, 5 fractions per week) up to a total of 44 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant LHRH agonists
Study NCT04310839 — intervention group
Intervention type: PROCEDURE
Intervention: Colectomy
Description: colectomy due to neoplastic (stage 1) or diverticulosis
Study NCT01804218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadolol
Study NCT01804218 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02072824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin Dose Level 1
Description: Pregabalin liquid dosed daily three times a day in equally divided doses escalated to 7.0 mg/kg/day beginning at Randomization through Taper Phase then tapered to 3.5 mg/kg/day during 1 week Taper Phase
Study NCT02072824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin Dose Level 2
Description: Pregabalin liquid dosed daily three times a day in equally divided doses escalated to 14.0 mg/kg/day beginning at Randomization through Taper Phase then tapered to 3.5 mg/kg/day during 1 week Taper Phase
Study NCT02072824 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Liquid dosed three times daily beginning at Randomization through Taper Phase
Study NCT03504995 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focal irreversible electroporation of the prostate cancer
Description: Irreversible electroporation is a non-thermal tissue ablation technique in which short duration electrical fields are used to permanently permeabilize the cell membrane.
Study NCT00513682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultrase® MT20
Description: Ultrase® MT20 capsules will be administered orally with each meal during Day 1 to 15 in screening phase at a dose based on investigator's discretion. During Day 12 to 15, participants will receive high-fat diet and Ultrase® MT20 dose will be adjusted depending on symptoms of steatorrhea. This will be followed by a washout phase of 6 to 7 days, in which participants will receive only high-fat diet; then stabilized dose of Ultrase® MT20 capsule (as identified during screening phase) will be administered orally for 7 to 11 days during treatment phase. The stabilized dose should not to exceed 2500 lipase units per kilogram body weight per meal (lipase units/kg/meal).
Study NCT02334865 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Incomplete Freund's Adjuvant
Description: Given SC
Study NCT02334865 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02334865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT02334865 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC
Study NCT02334865 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SVN53-67/M57-KLH Peptide Vaccine
Description: Given SC
Study NCT03992794 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of MR-proADM
Description: It is an observational study. The only intervention was the measure of MR-proADM, but no clinical decision was made based on its value, since the physician attending the patient did´n know the value of MR-proADM
Study NCT01674413 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Adalimumab 40 mg q 2 weeks, with placebo loading of 3 syringes/1 syringe at Weeks 0/2, 12/14, 24/26, and 36/38
Study NCT01674413 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab PRN
Description: 160 mg/80 mg Adalimumab at Weeks 0 and 2, followed by 1 syringe SC placebo q 2 weeks (except at Weeks 12/14, 24/26, and 36/38), with~* PRNLOADing of 160 mg/80 mg Adalimumab at Weeks 12/14, 24/26, or 36/38 if most recent FCP is ≥167 mcg/gram of stool,~* Or, placebo loading of 4 syringes/2 syringes at Weeks 12/14, 24/26, and 36/38 if most recent FCP is \< 167 mcg/gram of stool.
Study NCT01674413 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 syringe of placebo SC q 2 weeks, with additional placebo loading of 3 syringes/1 syringe at Weeks 0/2, 12/14, 24/26, and 36/38 Weeks.
Study NCT02880748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water exchange (WE) method
Description: Water exchange (WE) method was used for insertion to the cecum. And air was insufflated to distend the lumen for inspection and biopsy or polypectomy during withdrawal procedure.
Study NCT02880748 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Air insufflation (AI) method.
Description: Air insufflation (AI) method was used for insertion to the cecum. And air was insufflated to distend the lumen for inspection and biopsy or polypectomy during withdrawal procedure.
Study NCT00855803 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Description: Given in 1 or 5 fractions
Study NCT01487070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macugen (Pegaptanib Sodium)
Description: Pegaptanib sodium drug substance is a pegylated (40 kDa branched PEG molecule consisting of two 20 kDa PEG arms) anti-VEGF aptamer. It is formulated in phosphate buffered saline at pH 6-7. Sodium hydroxide or hydrochloric acid may be added for pH adjustment.~Pegaptanib sodium is formulated at 0.3mg/90µl and presented in a USP Type I glass barrel syringe sealed with a bromobutyl rubber stopper. A 30-guage needle is fixed to the end of the syringe after removal of the rubber stopper. The syringe comes in a sealed foil pouch, and the 30-gauge needle is added to the sterile injection field separately. The drug product is preservative-free and intended for single use by intravitreous injection only.
Study NCT00908921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLIMEPIRIDE
Description: Dosage of 1mg, 2mg and 4mg of AMARYL (Glimepiride)
Study NCT02218112 — intervention group
Intervention type: PROCEDURE
Intervention: bariatric surgery (gastric bypass)
Study NCT02344420 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Self assessment score
Description: patient will complete a self assessment questionnaire at 2, 6 and 12 month FU for the calculation of the Packer Score at 12 month.
Study NCT04282057 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency
Description: Radiofrequency protocol - The radiofrequency protocol was performed in dorsal decubitus, with the head elevated at 45 degrees. The application was in capacitive mode, with a 7cm electrode, always in movement. The duration of the application was established in 15 minutes, maintaining the local temperature between 40 to 42 celsius degrees at the epidermis.
Study NCT03767881 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AXIOS(TM) Stent and Electrocautery Enhanced Delivery System
Description: Patients who are at high risk or unsuitable for surgery will receive an AXIOS stent under EUS guidance for treatment of acute cholecystitis.
Study NCT02341066 — intervention group
Intervention type: DEVICE
Intervention: Endothelial Dysfunction evaluation by EndoPAT
Description: Endothelial dysfunction will be measured assessing reactive hyperemia of digital arteries by using Endo-PAT2000 (Itamar, Israel).
Study NCT02827721 — intervention group
Intervention type: DEVICE
Intervention: impulse oscillometry
Study NCT02993393 — intervention group
Intervention type: OTHER
Intervention: Teacher
Description: The teachers' questionnaire based on table of specification of the learning contents, consisted of 4 parts: airway evaluation, patient preparation, strategic planning and follow up care.
Study NCT02993393 — intervention group
Intervention type: OTHER
Intervention: Student
Description: The students' questionnaire comprised 3 parts: learning content, process and evaluation.
Study NCT01655914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flumazenil
Study NCT04282057 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: Aerobic exercise protocol - 40 minutes of aerobic moderate-intensity exercise (45-55% of reserve heart rate) using Karvonen's formula, performed on a cycloergometer. The duration of the exercise was divided into three parts: warm-up (5 minutes); body (30 minutes); and cooling (from 5 to 10 minutes). The entire protocol was monitored through the Polar® brand heart rate monitor and watch.
Study NCT04282057 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shock wave therapy
Description: The shock wave device corresponds to the BTL-6000 X-Wave TM with a 20mm transmitter multifocal. The parameters used correspond to the pressure set between 2.8 and 3.5 bar, frequency 15 hertz and 3000 pulses per 10x15 cm area. It was used as a means contact gel for ultrasound, reference 033-051. In this procedure the participants found themselves in the supine position, with a pillow under the head and with the bending knees.
Study NCT01231360 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Training
Description: Subjects randomized to exercise training will participate in a three-month treadmill exercise program in 1-hour training sessions three times per week as previously described. After a 5-minute warm-up period, exercise is initiated at a low workload of 2 mph at 0% grade. Subjects walk until moderate claudication severity develops, and then rest until the discomfort resolves, repeating until the total exercise period is completed. The intensity of the treadmill exercise is increased as tolerated by increasing walking speed by 0.5-1 mph and/or grade by 1-2%. Subjects are encouraged to continue the walking program at home for at least 30 minutes on two separate occasions each week.
Study NCT01231360 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal routine
Description: Subjects randomized to the routine activity control group will be asked to keep a log of their daily activities and return to the Vascular Research Center at weeks 4, 8, and 12 at which time they will be asked to return their log and undergo repeat treadmill testing and complete the 6 minute walk test.
Study NCT03386578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)
Description: 200 mg/300 mg of FTC/TDF administered orally as a fixed-dose combination tablet once daily
Study NCT03386578 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral HIV risk reduction package
Description: HIV risk reduction package, including cohort-appropriate SMS messages. Participants in the PrEP Comparison Component: Cohort 1 will also receive enhanced adherence support, including two-way SMS messaging and tailored counseling with near-real time drug level feedback.
Study NCT03386578 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral HIV risk reduction package
Description: HIV risk reduction package, including cohort-appropriate SMS messages. Participants in the PrEP Comparison Component: Cohort 1 will also receive enhanced adherence support, including two-way SMS messaging and tailored counseling with near-real time drug level feedback.
Study NCT01684475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJH1 (CLR4001)
Study NCT01036490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise training for 12 weeks followed by home exercise for 40 weeks